CLINICAL TRIALS PROFILE FOR ORUDIS

All Clinical Trials for ORUDIS

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00688961 ↗	Effects of Omacor and Aspirin on Platelet Function	Completed	Sanford Research	Early Phase 1	2007-06-01	Omacor (now Lovaza) is a pharmaceutical omega-3 fatty acid product. Omega-3 fatty acids can affect blood clotting by altering the function of the blood platelets. Aspirin can do the same. The purpose of this study is to determine the individual and combined effects of these two agents on platelet function using a whole blood method.
NCT02099006 ↗	Novel Topical Therapies for the Treatment of Genital Pain	Completed	Mae Stone Goode Foundation	Phase 2/Phase 3	2013-11-01	This study is testing drugs not previously used topically for the treatment of vulvodynia, a common genital pain syndrome. It is hoped that one of these drugs will improve vaginal entryway pain with touch, daily pain scores and sexual functioning.
NCT02099006 ↗	Novel Topical Therapies for the Treatment of Genital Pain	Completed	University of Rochester	Phase 2/Phase 3	2013-11-01	This study is testing drugs not previously used topically for the treatment of vulvodynia, a common genital pain syndrome. It is hoped that one of these drugs will improve vaginal entryway pain with touch, daily pain scores and sexual functioning.

Clinical Trial Conditions for ORUDIS

Condition Name

Condition Name for ORUDIS
Intervention	Trials
Healthy	1
Female Genital Diseases	1

Condition MeSH

Condition MeSH for ORUDIS
Intervention	Trials
Genital Diseases, Female	1

Clinical Trial Locations for ORUDIS

Trials by Country

Trials by Country for ORUDIS
Location	Trials
United States	2

Trials by US State

Trials by US State for ORUDIS
Location	Trials
New York	1
South Dakota	1

Clinical Trial Progress for ORUDIS

Clinical Trial Phase

Clinical Trial Phase for ORUDIS
Clinical Trial Phase	Trials
Phase 2/Phase 3	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for ORUDIS
Clinical Trial Phase	Trials
Completed	2

Clinical Trial Sponsors for ORUDIS

Sponsor Name

Sponsor Name for ORUDIS
Sponsor	Trials
Sanford Research	1
Mae Stone Goode Foundation	1
University of Rochester	1

Sponsor Type

Sponsor Type for ORUDIS
Sponsor	Trials
Other	3

ORUDIS Market Analysis and Financial Projection

Last updated: May 3, 2026

ORUDIS: Clinical Trials Update, Market Analysis, and 5-Year Projection

What is ORUDIS?

No complete, reliable product identity is available in the provided prompt. Without the active ingredient (INN), dosage form/strength, sponsor, and regulatory status, a clinical trials update and market projection for “ORUDIS” cannot be produced accurately.

What clinical trials exist for ORUDIS?

No clinical trials dataset can be confirmed for “ORUDIS” from the information provided. A defensible trials update requires the drug’s specific identifier (INN or developer code), which is not present.

What is ORUDIS’ market size and competitive landscape?

A market analysis requires at minimum: the drug’s therapeutic area, indication(s), approved geography, and formulation. Those inputs are not present in the prompt, so market sizing and competitive mapping cannot be stated as facts.

What is the 5-year market projection for ORUDIS?

A 5-year projection requires confirmed indication(s), launch timing or development stage, unit economics, pricing assumptions grounded in comparable products, and forecast drivers (share, penetration, persistence). None can be derived from the prompt alone.

Key Takeaways

No data can be validated from the prompt to support a clinical trials update, market sizing, competitive assessment, or a 5-year forecast for ORUDIS.

FAQs

1. What does “ORUDIS” refer to?
2. Is ORUDIS approved in any country?
3. Which indication(s) is ORUDIS targeting?
4. Who is the developer/sponsor of ORUDIS?
5. Are there active trials registered under the name ORUDIS?

References

[1]